Is there a cloud in the silver lining for imatinib?

被引：21

作者：

Paterson, SC

Smith, KD

Holyoake, TL

Jorgensen, HG

机构：

[1] Univ Glasgow, Royal Infirm, Div Canc Sci & Mol Pathol, Haematooncol Sect, Glasgow G31 2ER, Lanark, Scotland

[2] Univ Strathclyde, Royal Coll, Dept Biosci, Glasgow G1 1XW, Lanark, Scotland

来源：

BRITISH JOURNAL OF CANCER | 2003年 / 88卷 / 07期

关键词：

CML; imatinib; drug resistance;

D O I：

10.1038/sj.bjc.6600828

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Imatinib mesylate (Gleevec(R) or Glivec(R)), a small molecule tyrosine kinase inhibitor for the treatment of chronic myeloid leukaemia, has been said to herald the dawn of a new er-a of rationally designed, molecularly targeted oncotherapy. Lurking on the same new horizon, however, is the age-old spectre of drug resistance. This review sets the intoxicating clinical perspective against the more sobering laboratory evidence of such divergent mechanisms of imatinib resistance as gene amplification and stem cell quiescence. Polychemotherapy has already been considered to combat resistance, but a more innovative, as yet unformulated, approach may be advocated.

引用

页码：983 / 987

页数：5

共 39 条

[1] DETERMINANTS OF PLASMA ALPHA-1-ACID GLYCOPROTEIN (AAG) CONCENTRATIONS IN HEALTH [J].

BLAIN, PG ;

MUCKLOW, JC ;

RAWLINS, MD ;

ROBERTS, DF ;

ROUTLEDGE, PA ;

SHAND, DG .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 20 (05) :500-502

[2] High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance [J].

Branford, S ;

Rudzki, Z ;

Walsh, S ;

Grigg, A ;

Arthur, C ;

Taylor, K ;

Herrmann, R ;

Lynch, KP ;

Hughes, TP .

BLOOD, 2002, 99 (09) :3472-3475

[3] Pharmacogenetics of the human drug-transporter gene MDR1:: impact of polymorphisms on pharmacotherapy [J].

Brinkmann, U ;

Roots, I ;

Eichelbaum, M .

DRUG DISCOVERY TODAY, 2001, 6 (16) :835-839

[4]

Deininger MWN, 2001, BLOOD, V98, p176B

[5] Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J].

Demetri, GD ;

von Mehren, M ;

Blanke, CD ;

Van den Abbeele, AD ;

Eisenberg, B ;

Roberts, PJ ;

Heinrich, MC ;

Tuveson, DA ;

Singer, S ;

Janicek, M ;

Fletcher, JA ;

Silverman, SG ;

Silberman, SL ;

Capdeville, R ;

Kiese, B ;

Peng, B ;

Dimitrijevic, S ;

Druker, BJ ;

Corless, C ;

Fletcher, CDM ;

Joensuu, H .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :472-480

[6] Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells [J].

Druker, BJ ;

Tamura, S ;

Buchdunger, E ;

Ohno, S ;

Segal, GM ;

Fanning, S ;

Zimmermann, J ;

Lydon, NB .

NATURE MEDICINE, 1996, 2 (05) :561-566

[7] Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].

Druker, BJ ;

Talpaz, M ;

Resta, DJ ;

Peng, B ;

Buchdunger, E ;

Ford, JM ;

Lydon, NB ;

Kantarjian, H ;

Capdeville, R ;

Ohno-Jones, S ;

Sawyers, CL .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037

[8] Alpha-1-acid glycoprotein [J].

Fournier, T ;

Medjoubi-N, N ;

Porquet, D .

BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 2000, 1482 (1-2) :157-171

[9] Role of α1 acid glycoprotein in the in vivo resistance of human BCR-ABL+ leukemic cells to the Abl inhibitor STI571 [J].

Gambacorti-Passerini, C ;

Barni, R ;

le Coutre, P ;

Zucchetti, M ;

Cabrita, G ;

Cleris, L ;

Rossi, F ;

Gianazza, E ;

Brueggen, J ;

Cozens, R ;

Pioltelli, P ;

Pogliani, E ;

Corneo, G ;

Formelli, F ;

D'Incalci, M .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (20) :1641-1650

[10] Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification [J].

Gorre, ME ;

Mohammed, M ;

Ellwood, K ;

Hsu, N ;

Paquette, R ;

Rao, PN ;

Sawyers, CL .

SCIENCE, 2001, 293 (5531) :876-880

← 1 2 3 4 →